Articles

Selective inhibition of MCL1 overcomes venetoclax-resistance in a murine model of myelodysplastic syndromes

Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine
Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Smilow Cancer Center, Yale University School of Medicine, New Haven
Department of Medicine
Smilow Cancer Center, Yale University School of Medicine, New Haven
Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine
Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine; Department of Pediatrics
Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine
Vanderbilt-Ingram Cancer Center; Department of Pathology, Microbiology, and Immunology
Smilow Cancer Center, Yale University School of Medicine, New Haven
Department of Medicine; Cancer Biology Program, Vanderbilt University School of Medicine; Vanderbilt-Ingram Cancer Center; Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232
Haematologica Early view Aug 18, 2022 https://doi.org/10.3324/haematol.2022.280631